Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020;12:e8195.

PubMed  PubMed Central  Google Scholar 

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncol. 2019;21:v1–v100.

Article  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl J Med. 2005;352:987–96.

Article  CAS  PubMed  Google Scholar 

Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. 2022;3:6–10.

Article  PubMed  Google Scholar 

Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front Oncol. 2021;11:720501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.

Article  PubMed  PubMed Central  Google Scholar 

Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol, Immunother. 2016;65:1433–50.

Article  CAS  PubMed  Google Scholar 

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, et al. NK-92: an ‘off-the-shelf therapeutic’for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol, Immunother. 2016;65:485–92.

Article  CAS  PubMed  Google Scholar 

Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. BioMed Res Int. 2010;2010:956304.

Google Scholar 

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A, Bachmann M. Adaptor CAR platforms—next generation of T cell-based cancer immunotherapy. Cancers. 2020;12:1302.

Article  CAS  PubMed Central  Google Scholar 

Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler M-E, Middeke JM, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood, J Am Soc Hematol. 2021;137:3145–8.

CAS  Google Scholar 

Loff S, Dietrich J, Meyer J-E, Riewaldt J, Spehr J, von Bonin M, et al. Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. Mol Ther-Oncolytics. 2020;17:408–20.

Article  CAS  PubMed Central  Google Scholar 

Bachmann M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett. 2019;211:13–22.

Article  CAS  PubMed  Google Scholar 

Feldmann A, Hoffmann A, Bergmann R, Koristka S, Berndt N, Arndt C, et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology. 2020;9:1785608.

Article  PubMed Central  Google Scholar 

Kittel-Boselli E, Soto KEG, Loureiro LR, Hoffmann A, Bergmann R, Arndt C, et al. Targeting acute myeloid leukemia using the RevCAR platform: A programmable, switchable and combinatorial strategy. Cancers. 2021;13:4785.

Article  CAS  PubMed Central  Google Scholar 

Koristka S, Cartellieri M, Feldmann A, Arndt C, Loff S, Michalk I, et al. Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system. Blood. 2014;124:3494.

Article  Google Scholar 

Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun. 2018;90:116–31.

Article  CAS  PubMed  Google Scholar 

Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, et al. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020;10:2141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger AV, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6:e458.

Article  CAS  PubMed Central  Google Scholar 

Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, et al. From mono-to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018;9:25597.

Article  PubMed Central  Google Scholar 

Koristka S, Ziller-Walter P, Bergmann R, Arndt C, Feldmann A, Kegler A, et al. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. Cancer Immunol, Immunother. 2019;68:1401–15.

Article  CAS  Google Scholar 

Feldmann A, Arndt C, Koristka S, Berndt N, Bergmann R, Bachmann MP. Conventional CARs versus modular CARs. Cancer Immunol, Immunother. 2019;68:1713–9.

Article  Google Scholar 

Berndt N, Bippes CC, Michalk I, Bachmann D, Bachmann J, Puentes-Cala E, et al. Two Be or Not Two Be: The nuclear autoantigen La/SS-B is able to form dimers and oligomers in a redox dependent manner. Int J Mol Sci. 2021;22:3377.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carmo-Fonseca M, Pfeifer K, Schröder HC, Vaz MF, Fonseca JE, Müller WE, et al. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res. 1989;185:73–85.

Article  CAS  Google Scholar 

Yiannaki EE, Tzioufas AG, Bachmann M, Hantoumi J, Tsikaris M, Sakarellos-Daitsiotis M, et al. The value of synthetic linear epitope analogues of La/SSB for the detection of autoantibodies to La/SSB; specificity, sensitivity and comparison of methods. Clin Exp Immunol. 1998;112:152–8.

Article  CAS  PubMed Central  Google Scholar 

Albert S, Koristka S, Gerbaulet A, Cartellieri M, Arndt C, Feldmann A, et al. Tonic signaling and its effects on lymphopoiesis of CAR-armed hematopoietic stem and progenitor cells. J Immunol. 2019;202:1735–46.

Article  CAS  Google Scholar 

Soto KE, Loureiro LR, Bartsch T, Arndt C, Kegler A, Mitwasi N, et al. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells. Front Immunol. 2023;14:1302354.

Article  CAS  PubMed Central  Google Scholar 

Saleh HA, Mitwasi N, Ullrich M, Kubeil M, Toussaint M, Deuther-Conrad W, et al. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells. Front Immunol. 2023;14:1166169.

Article  CAS  PubMed Central  Google Scholar 

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl J Med. 2020;382:545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.

Article  PubMed  PubMed Central  Google Scholar 

Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T cell-based immunotherapy for the treatment of glioblastoma. Front Neurosci. 2021;15:662064.

Article  PubMed  PubMed Central  Google Scholar 

Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T CellsA Constitutively Active IL7 Receptor Enhances CAR T Cells. Cancer Discov. 2017;7:1238–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol. 2003;162:1313–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res. 2006;66:9535–42.

Article  CAS  PubMed  Google Scholar 

Perez JG, Tran NL, Rosenblum MG, Schneider CS, Connolly NP, Kim AJ, et al. The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene. 2016;35:2145–55.

Article  CAS  PubMed  Google Scholar 

Davis HE, Morgan JR, Yarmush ML. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophysical Chem. 2002;97:159–72.

Article  CAS